Relapsed AL Amyloidosis research hub

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

This study is testing a new cell therapy (AZD0120) for people with AL amyloidosis that has come back or not responded to previous treatments. It aims to see how safe and effective the treatment is.